CN101709066A - Novel crystallographic form of cocarboxylase tetrahydrate and method for preparing same - Google Patents
Novel crystallographic form of cocarboxylase tetrahydrate and method for preparing same Download PDFInfo
- Publication number
- CN101709066A CN101709066A CN200910235426A CN200910235426A CN101709066A CN 101709066 A CN101709066 A CN 101709066A CN 200910235426 A CN200910235426 A CN 200910235426A CN 200910235426 A CN200910235426 A CN 200910235426A CN 101709066 A CN101709066 A CN 101709066A
- Authority
- CN
- China
- Prior art keywords
- methyl
- tetrahydrate
- amino
- water
- pyrimidyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of medical chemistry, in particular to a novel crystallographic form of 4-methyl-3[(2-methyl-4-amino-5-pyrimidinyl)methyl]-5-(2-pyrophosphate acetyl oxygen ethyl) thiazolium tetrahydrates and a method for preparing the same. The X-ray powder diffractogram of the crystal has diffracted rays at the following d spaces: 0.666+/-0.004nm, 0.599+/-0.004nm, 0.562+/-0.004nm, 0.479+/-0.004nm, 0.433+/-0.004nm, 0.426+/-0.004nm, 0.407+/-0.004nm, 0.368+/-0.004nm, 0.362+/-0.004nm, 0.343+/-0.004nm, and 0.324+/-0.004nm, wherein the d space corresponding to the diffracted ray with the highest strength is 0.407+/-0.004nm or 0.343+/-0.004nm.
Description
Technical field
The invention belongs to the pharmaceutical chemistry field, be specially 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-new crystal of 5-(2-tetra-sodium acyl-oxygen ethyl) thiazole tetrahydrate and preparation method thereof.
Background technology
4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-5-(2-tetra-sodium acyl-oxygen ethyl) the general Cocarboxylase tetrahydrate by name of thiazole tetrahydrate (Cocarboxylase Tetrahydrate), have another name called four hydration cocarboxylase esters, be vitamin drug, the oxidative decarboxylation of pyruvic acid and a-ketoglutaric acid reaction in the involved in sugar metabolism in vivo, be that sugar metabolism institute is essential, during shortage, the oxidation formation pyruvic acid that is obstructed, lactic acid is piled up, and influencing the human body energy supply, its symptom mainly shows neural system, the cardiovascular system Digestive tract aspect etc. that unifies.Be usually used in the treatment of vitamin B1 deficiency or Wernicke encephalopathic clinically.Also can be used for the assisting therapy that Cocarboxylase tetrahydrate lacks the peripheral neuropathy cause, maldigestion etc.Its structure is:
When two or more crystalline state of certain compound formation, these different crystalline state are known as polymorphism, and stability changes along with every kind of polymorphous change of polymorphism.For example, pemetrexed disodium hydrate crystal forms patent has the disclosed 2.5 hydration crystal formations of WO0114379, and the disclosed heptahydrate crystal formation of WO0162760 also has the disclosed 3 hydration crystal formations of Chinese CN100364994C.These three kinds of crystal formations have different stability respectively, thereby the stability of long storage is exerted an influence.Equally, CN1275126 described specific a kind of in the different polymorphs bodies of Febuxostat be of value to store or working condition under keep its specific physical properties.
As mentioned above, specific polymorphic is dominant on stability, therefore, exists under multiple polymorphous situation, importantly works out the technology of every kind of polymorphs body of preferential preparation; Particularly, contain in production under the situation of pharmaceutical composition of medicinal active compound, suitably polymorphic is controlled and prepared the pharmaceutical composition that contains the specific polymorphs body that is dominant.
UK880573 has described the method for preparing diphosphothiamine hydrochloride, vitriol, nitrate etc. by Cocarboxylase tetrahydrate, and also introduced the preparation method of Cocarboxylase tetrahydrate, but the crystal formation to Cocarboxylase tetrahydrate is not mentioned at document, does not disclose the crystal formation physical property of tetrahydrate yet.(JAMES PLETCHER such as JAMES PLETCHER, MICAL WOOD.Thiaminepyrophosphate tetrahydrate:A Structure with the Pyrophosphate Ester in an ExtendedConformation, Acta Cryst. (1977) .B33,3349-3359) a kind of crystal formation is disclosed, we study the Cocarboxylase tetrahydrate crystal formation, we have found a kind of crystal formation that is different from the new Cocarboxylase tetrahydrate of prior art bibliographical information in this process, and the corresponding d-spacing of characteristic spectral line is 0.407 ± 0.004nm or 0.343 ± 0.004nm in its X-ray powder diffraction pattern.This crystal formation is difficult for dehydration, also is difficult for moisture absorption, and steady quality is easy to store, and preparation and purification process are simple.
Summary of the invention
The invention provides a kind of stability better, the simple Cocarboxylase tetrahydrate crystal formation of preparation, it does not have tangible fluid loss property and water absorbability in normal condition, can prolonged preservation.
4-methyl of the present invention-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-crystal formation of 5-(2-tetra-sodium acyl-oxygen ethyl) thiazole salt tetrahydrate, its X-ray powder diffraction has diffracted ray in following d spacing: 0.666 ± 0.004nm, 0.599 ± 0.004nm, 0.562 ± 0.004nm, 0.479 ± 0.004nm, 0.433 ± 0.004nm, 0.426 ± 0.004nm, 0.407 ± 0.004nm, 0.368 ± 0.004nm, 0.362 ± 0.004nm, 0.343 ± 0.004nm, 0.324 ± 0.004nm, wherein the diffracted ray of intensity maximum uses the copper gamma ray source to measure under envrionment temperature and ambient moisture and obtains corresponding to d spacing 0.407 ± 0.004nm or 0.343 ± 0.004nm.
4-methyl of the present invention-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-preparation method of the crystal formation of 5-(2-tetra-sodium acyl-oxygen ethyl) thiazole salt tetrahydrate, for making 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-separate out crystallization in the non-aqueous solvent that 5-(2-tetra-sodium acyl-oxygen ethyl) thiazole salt can dissolve each other at water or with water, filter, drying under reduced pressure obtains; Wherein the solvent that can dissolve each other with water can be one of ethanol, methyl alcohol, Virahol, acetone, tetrahydrofuran (THF), ethylene glycol or their mixture; Solvent can preferred alcohol.Drying under reduced pressure is a common process.
The present invention has comprised a kind of pharmaceutical composition, by 4-methyl of the present invention-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-5-(2-tetra-sodium acyl-oxygen ethyl) thiazole salt tetrahydrate crystal formation and acceptable accessories or carrier form.
Acceptable accessories or carrier such as oral preparations are used auxiliary material always, the injection auxiliary material, and be prepared to dosage forms such as oral preparation such as tablet, capsule, particle, injection liquid, freeze-dried powder, the auxiliary material that is adopted, carrier and preparation technique are general known technology, in pharmaceutics (Higher Education Publishing House, the 4th edition) etc. have a detailed description in the books, dosage form and specification of quality thereof are described with existing Chinese Pharmacopoeia and are as the criterion.
Cocarboxylase tetrahydrate of the present invention can be used for preparing the medicine for the treatment of thiamine deficiency, for meeting clinical needs, can be prepared into the single active agent preparation of this product, also can be the composite vitamin supplementing preparation of forming with other vitamin ingredients.
The X-ray powder diffraction analysis of Cocarboxylase tetrahydrate of the present invention is under envrionment temperature and ambient moisture, through the Cu K of Japanese Rigaku D/max-2400X-ray powder diffraction instrument
α 1=1.54056A mensuration is finished.This hydrate has typical X-ray powder diffraction, and measuring error is ± 0.004nm its relative intensity (I/I
0) diffracted ray greater than 30% and corresponding interplanar distance (d) list in the table 1.
It generally is 0～40 ℃ that hydrate of the present invention carries out X-ray powder diffraction survey periodic " envrionment temperature "; " ambient moisture " generally is 30%～80% relative humidity.
Table 1 Cocarboxylase tetrahydrate X-of the present invention ray powder diffraction data
| D-interplanar distance (nm) | Relative intensity I/I 0(％) | D-interplanar distance (nm) | Relative intensity I/I 0(％) |
| ??0.666 | ??82.3 | ??0.599 | ??42.1 |
| ??0.562 | ??64.0 | ??0.479 | ??36.1 |
| ??0.434 | ??51.6 | ??0.426 | ??67.9 |
| ??0.407 | ??100 | ??0.368 | ??46.9 |
| ??0.362 | ??32.8 | ??0.343 | ??85.5 |
Annotate: surveying periodic envrionment temperature is 24 ℃, and ambient relative humidity is 60%.
The diffracted ray that Cocarboxylase tetrahydrate crystal formation of the present invention is characterised in that relative intensity maximum on its X-ray powder diffraction is corresponding to following d spacing: 0.407 ± 0.004nm or 0.343 ± 0.004nm.The contained crystallization water number of Cocarboxylase tetrahydrate provided by the invention is 4, and we have proved conclusively the number of crystal water by monocrystalline X-diffraction, the chemical space structure is seen Fig. 1, wherein 01W, 02W, 03W, 04W, 05W, 06W, 07W, 08W represent 8 water moleculess, thereby have proved that diphosphothiamine is classified as with the ratio of water molecules in this crystal structure: 1: 4.This crystal contains four crystal water.
The present invention also with this monocrystalline with from water respectively with methyl alcohol, ethanol, acetone, tetrahydrofuran (THF) mixing solutions the maximum and time maximum diffracted ray of relative intensity in the Cocarboxylase tetrahydrate X-ray powder diffraction separated out and corresponding d-spacing compare, list in the table 2.
Characteristic spectral line in the crystallization X-ray powder diffraction that crystallization obtains in table 2 Cocarboxylase tetrahydrate monocrystalline and the different solvents
As can be seen from Table 2, relative intensity maximum absorption band basically identical in the X-ray powder diffraction of hydrate crystal forms of the present invention illustrates that above several crystal formations are consistent.
4-methyl-3-[(2-methyl-4-amino-5-the pyrimidyl that makes involved in the present invention) methyl]-hydrate of 5-(2-tetra-sodium acyl-oxygen ethyl) thiazole salt is from comprising 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-5-(2-tetra-sodium acyl-oxygen ethyl) thiazole salt, water and with the miscible solvent of water crystallize out, drying under reduced pressure then, concrete method condition is as follows:
1) diphosphothiamine hydrochloride or other acid group salt added in the entry dissolve, splash into then and equimolar 10% ammonia soln of acid group, in and acid group, if do not clarify, can filter.
2) control this solution temperature between 0～100 ℃, preferred 10～40 ℃.
3) under the room temperature to this solution add 2～20 times of volumes can be miscible with water solvent, this solvent includes but not limited to ethanol, methyl alcohol, Virahol, acetone, tetrahydrofuran (THF), ethylene glycol or their mixed solvent, preferred alcohol (comprising dehydrated alcohol and aqueous ethanol) wherein, the preferred 4-6 of used volume are doubly; In adding the alcoholic acid process, ethanol is slowly dripped, so not only make the crystal formation of separating out better, and can remove impurity; When finishing soon, dropping ethanol have the off-white color solid to separate out.
4) filter collecting the solid of separating out is Cocarboxylase tetrahydrate.Can wash with dehydrated alcohol or aqueous ethanol (water content is generally less than 5%).If the gained Cocarboxylase tetrahydrate need be further purified, can repeat above-mentioned crystallization step.
5) drying under reduced pressure, temperature generally are 20～50 ℃, preferred 20～40 ℃; Vacuum tightness generally is-0.09Mpa; Particular cases such as the temperature when time of drying, lower limit was according to drying, vacuum tightness, thickness of sample are decided, and time of drying, the upper limit did not make significant difference to crystal formation of the present invention, generally was no more than 24 hours.
6) Cocarboxylase tetrahydrate moisture content of the present invention generally is 14%～16% (the theoretical water content of tetrahydrate crystal formation is 14.5%).
Preparation method's decapacitation provided by the invention is prepared outside the Cocarboxylase tetrahydrate, can also optionally separate out impurity and comes purified product by adjusting pure water ratio.From whole technology, this preparation method controllability is strong, and is easy and simple to handle, and favorable reproducibility is all used conventional equipment, is easy to suitability for industrialized production.
For the stability of the crystal water of investigating Cocarboxylase tetrahydrate crystal formation of the present invention, this product is exposed under the environment of 25 ℃ and 50% relative humidity, investigate water content over time, testing data sees Table 3.
Table 3 Cocarboxylase tetrahydrate crystal formation water absorbability is investigated
| Time | 0 hour | 3 |
9 |
12 hours | 24 hours |
| Water content (%) | ??14.1 | ??14.1 | ??14.2 | ??14.2 | ??14.3 |
From table 3 testing data as can be seen, tetrahydrate crystal formation (theoretical water content is 14.5%) does not have water absorbability substantially under this experiment condition, and stable crystal form is good.
In order further to investigate Cocarboxylase tetrahydrate crystal formation crystal water stable content of the present invention, this product sealing is kept under 40 ℃ and the environment that has siccative to exist tested 6 months, its water content of periodic measurement, testing data sees Table 4.
The investigation of table 4 Cocarboxylase tetrahydrate crystal formation crystal water stable content
| Time | 0 month | January | February | March | June |
| Water content (%) | ??14.3 | ??14.3 | ??14.3 | ??14.2 | ??14.2 |
From the experimental result of table 4 as can be seen, tetrahydrate water content of the present invention is basicly stable.This presentation of results Cocarboxylase tetrahydrate of the present invention has the advantage of stability aspect fluid loss property.And this product crystal water also is described 100 ℃ of beginning dehydrations by tests such as DSC, TGA, 180 ℃ of dehydrations be 14.05% with crystal water content basically identical, thereby further specify the advantage that this product tetrahydrate has stability.
Generally speaking, Cocarboxylase tetrahydrate of the present invention has typical X-ray powder diffraction feature, and its no hygroscopicity and fluid loss property, and preparation technology is simple and easy to do, and therefore tetrahydrate of the present invention has long-range utility value.
Cocarboxylase tetrahydrate of the present invention can be used as active constituent and is used for the avitaminotic medicine of preparation treatment.Generally be with treatment effectively this crystallization and one or more pharmaceutical carriers or vehicle make pharmaceutical preparation, this pharmaceutical preparation is to be prepared in the mode of knowing in the pharmacy field.Carrier or vehicle can be solid, semisolid or liquid substance, and they are as the carrier or the medium of active ingredient, and suitable carriers or vehicle are to know in this area.That pharmaceutical composition goes for is oral, use on suction, parenteral administration or surface; Formulation includes but not limited to injection, pharmaceutical solutions, tablet, capsule, granule, aerosol, suppository, gelifying agent etc.Optimizing injection wherein, freeze-dried powder formulation most preferably, during use with solution form drug administration by injection.
Can be in the preparation of compositions process of freeze-dried powder form including but not limited to following one or more auxiliary agents; Aseptic thinner such as injection water, salt brine solution such as sodium-chlor, N.F,USP MANNITOL, fixed oil, polyoxyethylene glycol, glycerine, propylene glycol or other synthetics; Antiseptic-germicide such as phenylcarbinol, methyl p-hydroxybenzoate etc.; Antioxidant such as xitix, sodium bisulfite etc.; Sequestrant such as sodium ethylene diamine tetracetate calcium etc.; Buffer reagent such as acetate, Citrate trianion or phosphoric acid salt etc.; Be used to regulate infiltrative reagent such as sodium-chlor, glucose etc.
With diphosphothiamine of the present invention or tetrahydrate is the preparation that active constituent is made, and is used for the treatment of vitamin deficiency.
Prepared Cocarboxylase tetrahydrate quality controlling means of the present invention and requirement, can for:
(1), assay is measured according to high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2005).
Chromatographic condition and system suitability test are weighting agent with amino chemically bonded silica, and (transferring pH to 7.4 with phosphoric acid)-methyl alcohol (57: 43) is moving phase to the aqueous dibasic potassium phosphate solution of 0.1mol/L, detects wavelength 234nm.Theoretical plate number is pressed the Cocarboxylase tetrahydrate peak and is calculated, and should be not less than 1500.
It is an amount of that the assay method precision takes by weighing this product, makes the solution that contains Cocarboxylase tetrahydrate 200 μ g among every 1ml approximately with moving phase, as need testing solution; Precision is measured 20 μ l and is injected liquid chromatograph, the record color atlas; Other gets the Cocarboxylase tetrahydrate reference substance, measures with method, presses external standard method with calculated by peak area, promptly.
(2), related substance gets this product, adds moving phase dissolving and dilution and makes the solution that contains Cocarboxylase tetrahydrate 1.0mg among every 1ml approximately, shake up, as need testing solution; Precision is measured need testing solution 1ml, puts in the 100m1 measuring bottle, adds moving phase and is diluted to scale, shakes up, in contrast solution.According to the chromatographic condition under the assay item, get contrast solution 20 μ l and inject liquid chromatograph, regulate instrumental sensitivity, make the principal constituent peak height be about 20%～30% of registering instrument full range.Precision is measured contrast solution and each 20 μ l of need testing solution respectively again, injects liquid chromatograph respectively, and the record color atlas is to 2 times of principal constituent peak retention time.In the color atlas of need testing solution as show impurity peaks, the peak area of maximum contaminant must not be crossed half (0.5%) of the main peak area of contrast solution, each impurity peak area and must not be greater than the main peak area (1.0%) of contrast solution.
(3), moisture gets this product, measures according to aquametry (two appendix VIII of Chinese Pharmacopoeia version in 2005 M, the first method A), contain moisture and should be 14.0%～16.0%.
Embodiment
Following examples just are described more specifically the present invention, and the present invention is not limited in the content of following examples.
In the reaction flask of 2L, add 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-5-(2-tetra-sodium acyl-oxygen ethyl) thiazole hydrochloride (diphosphothiamine hydrochloride) 20.0g (0.043mol) is dissolved in the 200ml distilled water, slowly splash into 10% ammonia soln 3.0ml again, drip dehydrated alcohol 400ml under the room temperature, a large amount of solids are separated out, filter absolute ethanol washing and get off-white color solid wet product, these wet product directly are dissolved in the 200ml distilled water, slowly splash into dehydrated alcohol 400ml again, a large amount of solids are separated out, filter absolute ethanol washing, 35 ℃ of vacuum-dryings got off-white powder solid 17.3g, yield 81% in 12 hours, HPLC detection level 99.33%, single impurity 0.37%, total impurities 0.82%, moisture 15.61%; Its X-ray powder diffraction is seen Fig. 2, and the DSC collection of illustrative plates is seen Fig. 3, and the TGA collection of illustrative plates is seen Fig. 4.
In the reaction flask of 2L, add 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-5-(2-tetra-sodium acyl-oxygen ethyl) thiazole hydrochloride (diphosphothiamine hydrochloride) 20.0g (0.043mol) is dissolved in the 200ml distilled water, slowly splash into 10% ammonia soln 3.0ml again, drip dehydrated alcohol 400ml under the room temperature, a large amount of solids are separated out, filter absolute ethanol washing and get off-white color solid wet product, these wet product directly are dissolved in the 200ml distilled water, slowly splash into anhydrous methanol 400ml again, a large amount of solids are separated out, the washing of filtration anhydrous methanol, 35 ℃ of vacuum-dryings got off-white powder solid 14.3g, yield 67% in 12 hours.HPLC detection level 99.23%, single impurity 0.44%, total impurities 0.84%, moisture 15.60%; Its X-ray powder diffraction is seen Fig. 5, and the DSC collection of illustrative plates is seen Fig. 6, and the TGA collection of illustrative plates is seen Fig. 7.
Embodiment 3
In the reaction flask of 2L, add 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-5-(2-tetra-sodium acyl-oxygen ethyl) thiazole hydrochloride (diphosphothiamine hydrochloride) 20.0g (0.043mol) is dissolved in the 200ml distilled water, slowly splash into 10% ammonia soln 3.0ml again, drip dehydrated alcohol 400ml under the room temperature, a large amount of solids are separated out, filter absolute ethanol washing and get off-white color solid wet product, these wet product directly are dissolved in the 200ml distilled water, slowly splash into acetone 400ml again, a large amount of solids are separated out, filter washing with acetone, 35 ℃ of vacuum-dryings got off-white powder solid 14.5g, yield 68% in 12 hours.HPLC detection level 99.21%, single impurity 0.46%, total impurities 0.85%, moisture 15.67%; Its X-ray powder diffraction is seen Fig. 8, and the DSC collection of illustrative plates is seen Fig. 9, and the TGA collection of illustrative plates is seen Figure 10.
Embodiment 4
In the reaction flask of 2L, add 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-5-(2-tetra-sodium acyl-oxygen ethyl) thiazole hydrochloride (diphosphothiamine hydrochloride) 20.0g (0.043mol) is dissolved in the 200ml distilled water, slowly splash into 10% ammonia soln 3.0ml again, drip dehydrated alcohol 400ml under the room temperature, a large amount of solids are separated out, filter absolute ethanol washing and get off-white color solid wet product, these wet product directly are dissolved in the 200ml distilled water, slowly splash into tetrahydrofuran (THF) 500ml again, a large amount of solids are separated out, the washing of filtration tetrahydrofuran (THF), 35 ℃ of vacuum-dryings got off-white powder solid 15.5g, yield 73% in 12 hours.HPLC detection level 99.11%, single impurity 0.43%, total impurities 0.75%, moisture 15.64%; Its X-ray powder diffraction is seen Figure 11.
Embodiment 5
In the reaction flask of 2L, add 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-5-(2-tetra-sodium acyl-oxygen ethyl) thiazole hydrochloride (diphosphothiamine hydrochloride) 20.0g (0.043mol) is dissolved in the 200ml distilled water, slowly splash into 10% ammonia soln 3.0ml again, drip dehydrated alcohol 400ml under the room temperature, a large amount of solids are separated out, filter absolute ethanol washing and get off-white color solid wet product, these wet product directly are dissolved in the 200ml distilled water, slowly splash into Virahol 450ml again, a large amount of solids are separated out, filter washed with isopropyl alcohol, 35 ℃ of vacuum-dryings got off-white powder solid 18.5g, yield 87% in 12 hours.HPLC detection level 99.14%, single impurity 0.42%, total impurities 0.81%, moisture 14.58%; Its X-ray powder diffraction is seen Figure 12.
Embodiment 6
In the reaction flask of 2L, add 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-5-(2-tetra-sodium acyl-oxygen ethyl) thiazole hydrochloride (diphosphothiamine hydrochloride) 20.0g (0.043mol) is dissolved in the 200ml distilled water, slowly splash into 10% ammonia soln 3.0ml again, drip dehydrated alcohol 400ml under the room temperature, a large amount of solids are separated out, filter absolute ethanol washing and get off-white color solid wet product, these wet product directly are dissolved in the 200ml distilled water, slowly splash into ethylene glycol 550ml again, a large amount of solids are separated out, the washing of filtration ethylene glycol, 35 ℃ of vacuum-dryings got off-white powder solid 11.5g, yield 54% in 12 hours.HPLC detection level 99.18%, single impurity 0.46%, total impurities 0.77%, moisture 14.88%; Its X-ray powder diffraction is seen Figure 13.
Description of drawings
Fig. 1 is the chemical space structure iron of Cocarboxylase tetrahydrate of the present invention.
Fig. 2 is the Cocarboxylase tetrahydrate crystal form X-ray powder diffraction of the embodiment of the invention 1.
Fig. 3 is the Cocarboxylase tetrahydrate crystal formation DSC collection of illustrative plates of the embodiment of the invention 1.
Fig. 4 is the Cocarboxylase tetrahydrate crystal formation TGA collection of illustrative plates of the embodiment of the invention 1.
Fig. 5 is the Cocarboxylase tetrahydrate crystal form X-ray powder diffraction of the embodiment of the invention 2.
Fig. 6 is the Cocarboxylase tetrahydrate crystal formation DSC collection of illustrative plates of the embodiment of the invention 2.
Fig. 7 is the Cocarboxylase tetrahydrate crystal formation TGA collection of illustrative plates of the embodiment of the invention 2.
Fig. 8 is the Cocarboxylase tetrahydrate crystal form X-ray powder diffraction of the embodiment of the invention 3.
Fig. 9 is the Cocarboxylase tetrahydrate crystal formation DSC collection of illustrative plates of the embodiment of the invention 3.
Figure 10 is the Cocarboxylase tetrahydrate crystal formation TGA collection of illustrative plates of the embodiment of the invention 3.
Figure 11 is the Cocarboxylase tetrahydrate crystal form X-ray powder diffraction of the embodiment of the invention 4.
Figure 12 is the Cocarboxylase tetrahydrate crystal form X-ray powder diffraction of the embodiment of the invention 5.
Figure 13 is the Cocarboxylase tetrahydrate crystal form X-ray powder diffraction of the embodiment of the invention 6.
Claims (5)
1. methyl 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl)]-crystal formation of 5-(2-tetra-sodium acyl-oxygen ethyl) thiazole salt tetrahydrate, it is characterized in that this crystalline X-ray powder diffraction figure has diffracted ray in following d spacing: 0.666 ± 0.004nm, 0.599 ± 0.004nm, 0.562 ± 0.004nm, 0.479 ± 0.004nm, 0.433 ± 0.004nm, 0.426 ± 0.004nm, 0.407 ± 0.004nm, 0.368 ± 0.004nm, 0.362 ± 0.004nm, 0.343 ± 0.004nm, 0.324 ± 0.004nm, wherein the diffracted ray of intensity maximum is corresponding to d spacing 0.407 ± 0.004nm or 0.343 ± 0.004nm.
2. methyl preparation claim 1 described 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl)]-method of the crystal formation of 5-(2-tetra-sodium acyl-oxygen ethyl) thiazole salt tetrahydrate, it is characterized in that: make 4-methyl-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-separate out crystallization in the non-aqueous solvent that 5-(2-tetra-sodium acyl-oxygen ethyl) thiazole salt can dissolve each other at water or with water, filter, drying under reduced pressure obtains.
3. as method as described in the claim 2, be one of ethanol, methyl alcohol, Virahol, acetone, tetrahydrofuran (THF), ethylene glycol or their mixture wherein with the solvent that water can dissolve each other.
4. method as claimed in claim 2 is an ethanol with the solvent that can dissolve each other wherein.
5. a pharmaceutical composition comprises the described 4-methyl of claim 1-3-[(2-methyl-4-amino-5-pyrimidyl) methyl]-5-(2-tetra-sodium acyl-oxygen ethyl) thiazole salt tetrahydrate crystal formation and acceptable accessories or carrier.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910235426A CN101709066A (en) | 2009-10-23 | 2009-10-23 | Novel crystallographic form of cocarboxylase tetrahydrate and method for preparing same |
| CN2010101449664A CN101787049B (en) | 2009-09-23 | 2010-04-13 | Novel crystal form of cocarboxylase tetrahydrate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910235426A CN101709066A (en) | 2009-10-23 | 2009-10-23 | Novel crystallographic form of cocarboxylase tetrahydrate and method for preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101709066A true CN101709066A (en) | 2010-05-19 |
Family
ID=42401877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910235426A Pending CN101709066A (en) | 2009-09-23 | 2009-10-23 | Novel crystallographic form of cocarboxylase tetrahydrate and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101709066A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108191912A (en) * | 2017-12-29 | 2018-06-22 | 山西普德药业有限公司 | The preparation method of 12 kinds of vitamin raw materials Cocarboxylase Tetrahydrates of injection |
-
2009
- 2009-10-23 CN CN200910235426A patent/CN101709066A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108191912A (en) * | 2017-12-29 | 2018-06-22 | 山西普德药业有限公司 | The preparation method of 12 kinds of vitamin raw materials Cocarboxylase Tetrahydrates of injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101891738B (en) | Dasatinib polymorph and preparation method and medical composition thereof | |
| CN102086195B (en) | Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof | |
| CN101578283B (en) | Crystalline forms of thiazolidinedione derivative and manufacturing method thereof | |
| US6720188B2 (en) | Methods and kits for the detection of arginine compounds | |
| CN105175422B (en) | A kind of phosphoric acid Xi Gelieting crystal and its preparation method and application | |
| CN101671314A (en) | Uloric crystal and preparation method thereof | |
| CN100364994C (en) | Crystal form of Peimeiqusai disodium and its preparation | |
| CN106995397A (en) | R Amisulprides pharmaceutical salts, preparation method, crystal formation and application thereof | |
| CN101787049B (en) | Novel crystal form of cocarboxylase tetrahydrate and preparation method thereof | |
| CN106966944B (en) | Vildagliptin crystal form compound and preparation method thereof | |
| CN101709066A (en) | Novel crystallographic form of cocarboxylase tetrahydrate and method for preparing same | |
| CN106892900A (en) | A kind of Vonoprazan fumarate and preparation method thereof | |
| AU2021106179A4 (en) | New crystalline form of epalrestat as well as preparation method and application thereof | |
| CN102838602A (en) | Pemetrexed oxide and preparation method thereof | |
| CN102250084A (en) | Dasatinib polymorphic substance as well as preparation method and pharmaceutical composition thereof | |
| CN111217757B (en) | Enzalutamide compound and pharmaceutical composition preparation thereof | |
| CN104829660A (en) | Isomer of clindamycin phosphate | |
| US20140011856A1 (en) | Salt form of tyrosine kinase inhibitor | |
| CN103396378B (en) | Stable febuxostat crystal | |
| CN103804366B (en) | Lafutidine crystal compound | |
| CN102408375B (en) | Ozagrel sodium compound | |
| CN103724359B (en) | A kind of amorphous cefotetan acid and prepared the method for Cefotetan Disodium and containing the pharmaceutical composition of this Cefotetan Disodium by it | |
| CN106905216A (en) | A kind of proton pump inhibitor medical compounds and preparation method thereof | |
| CN105601616A (en) | L-pantoprazole sodium 2.5-hydrate | |
| EP4049999A1 (en) | Crystal form of hypoxia-inducible factor-prolyl hydroxylase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100519 |